This study aimed to investigate the anticancer efficacy of a conjugated drug system, consisting of doxorubicin and cisplatin (Dox‐Cis), encapsulated within niosomes and modified with MUC‐1 aptamers to enhance biocompatibility and target specific cancer cells. Here, MUC1 is linked to cancer.